{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:33:55Z","timestamp":1792596835628,"version":"4.5.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>With an increasing prevalence, dementia is one of the most disabling diseases among the elderly. Impaired cognitive function and behavioral and psychological symptoms predispose patients to medication non-adherence, resulting in increased morbidity, mortality, and healthcare costs. The aim of this study was to estimate the prevalence of non-adherence to antidementia medications and to identify the main predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A population-based registry study was conducted in 2022 in Castile and Leon, Spain. A total of 17,563 patients with dementia were included. The medication possession ratio (MPR) was used as an indirect method to measure adherence. The cut-off point for determining that a patient was nonadherent was 80% of MPR. Multivariate logistic regression was used to identify predictors of nonadherence based on sociodemographic and health-related variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2022, 6.2% of the population over 80 years old used antidementia medications. Of these patients, 70% were women, 28.15% were institutionalized, and over 90% were polymedicated and had multiple prescribers. The most used medicines were donepezil (43.49%), rivastigmine (36.84%), and memantine (30.7%). The combined use of an acetylcholinesterase inhibitor plus memantine was relevant (13.33%). Men were less adherent than women, and the prevalence of non-adherence decreased with age. The medication associated with the highest prevalence of non-adherence was rivastigmine (19%), followed by donepezil (17%) and memantine (13.23%). Institutionalized patients (13%) and patients on combination therapy (13.29%) had the lowest prevalence of non-adherence. Protective factors against non-adherence include institutionalization, polymedication, use of memantine or combination therapy, and comorbid mental illness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Castile and Leon, one in six patients were non-adherent to antidementia medications. Younger male patients with cardiometabolic disease are more likely to be non-adherent to antidementia medications. On the other hand, institutionalization is a protective factor against non-adherence, but still 10% of nursing home patients are non-adherent to antidementia medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1425442","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T23:34:30Z","timestamp":1730763270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Non-adherence to antidementia medications and associated factors: a study of Spanish population-based registry data"],"prefix":"10.3389","volume":"15","author":[{"given":"Eduardo","family":"Guti\u00e9rrez-Abej\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ar\u00e1nzazu","family":"Pedrosa-Naud\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Fern\u00e1ndez-L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"D\u00edaz Planelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/ppa.s2652","article-title":"Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program","volume":"2","author":"Abughosh","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"B2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.12669\/pjms.36.4.1923","article-title":"Patterns of medication use and adherence to medications among residents in the elderly homes","volume":"36","author":"Algameel","year":"2020","journal-title":"Pak J. Med. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/pds.1946","article-title":"Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer\u2019s disease","volume":"19","author":"Amuah","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and management of dementia: review","volume":"322","author":"Arvanitakis","year":"2019","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11357-021-00470-7","article-title":"Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary","volume":"44","author":"Bal\u00e1zs","year":"2022","journal-title":"Geroscience"},{"key":"B8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1080\/09540260802099968","article-title":"Neuropsychiatric symptoms in dementia: importance and treatment considerations","volume":"20","author":"Ballard","year":"2008","journal-title":"Int. Rev. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","article-title":"A systematic review of medication adherence thresholds dependent of clinical outcomes","volume":"9","author":"Baumgartner","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"CD005593","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"2006","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1532-5415.2009.02075.x","article-title":"Adherence to cholinesterase inhibitors in patients with Alzheimer\u2019s disease","volume":"57","author":"Blais","year":"2009","journal-title":"J. Am. Geriatr. Soc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1017\/S1041610215000654","article-title":"Continuous treatment with antidementia drugs in Germany 2003-2013: a retrospective database analysis","volume":"27","author":"Bohlken","year":"2015","journal-title":"Int. Psychogeriatr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5414\/CP202572","article-title":"Persistence with antidepressant drugs in patients with dementia: a retrospective database analysis","volume":"54","author":"Booker","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1185\/03007995.2010.493788","article-title":"Predictors of adherence among Alzheimer\u2019s disease patients receiving oral therapy","volume":"26","author":"Borah","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"B15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ccm.2012.06.002","article-title":"Adherence: the goal to control asthma","volume":"33","author":"Boulet","year":"2012","journal-title":"Clin. Chest Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000347140","article-title":"Adherence to cholinesterase inhibitors in Alzheimer\u2019s disease: a review","volume":"35","author":"Brady","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00228-013-1483-y","article-title":"A population-based study of dosing and persistence with anti-dementia medications","volume":"69","author":"Brewer","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13900","DOI":"10.3390\/ijms241813900","article-title":"Treatment of alzheimer\u2019s disease: beyond symptomatic therapies","volume":"24","author":"Buccellato","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40266-017-0446-x","article-title":"Trends in the prescription and long-term utilization of antidementia drugs among patients with alzheimer\u2019s disease in Spain: a cohort study using the registry of dementias of girona","volume":"34","author":"Calv\u00f3-Perxas","year":"2017","journal-title":"Drugs Aging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.amjopharm.2012.04.004","article-title":"Medication adherence in older adults with cognitive impairment: a systematic evidence-based review","volume":"10","author":"Campbell","year":"2012","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2118441","DOI":"10.1001\/jamanetworkopen.2021.18441","article-title":"Comparison of medication prescribing before and after the COVID-19 pandemic among nursing home residents in ontario, Canada","volume":"4","author":"Campitelli","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B22","unstructured":"CONCYLIA, the pharmacy information system of castile and Leon2023"},{"key":"B23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.trci.2018.06.013","article-title":"Persistence and adherence to rivastigmine in patients with dementia: results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan","volume":"5","author":"Chang","year":"2019","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1080\/13607863.2011.596805","article-title":"Underdiagnosis of dementia in primary care: variations in the observed prevalence and comparisons to the expected prevalence","volume":"15","author":"Connolly","year":"2011","journal-title":"Aging Ment. Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"105636","DOI":"10.1016\/j.archger.2024.105636","article-title":"Prevalence of strong anticholinergic use in residents with and without cognitive impairment and frailty: analysis from 106 nursing homes in 12 Asia-Pacific and European countries","volume":"128","author":"Cross","year":"2024","journal-title":"Arch. Gerontol. Geriatr."},{"key":"B26","first-page":"55","article-title":"From Morisky to Hill-bone; self-reports scales for measuring adherence to medication","volume":"38","author":"Culig","year":"2014","journal-title":"Coll. Antropol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S2468-2667(17)30031-2","article-title":"Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study","volume":"2","author":"Donegan","year":"2017","journal-title":"Lancet Public Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3892\/etm.2013.1425","article-title":"Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: a meta-analysis","volume":"7","author":"Fang","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1345\/aph.1K514","article-title":"Prolonged QT interval, syncope, and delirium with galantamine","volume":"42","author":"Fisher","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3109\/00048670903555104","article-title":"Anticholinesterase duration in the Australian veteran population","volume":"44","author":"Gadzhanova","year":"2010","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.euroneuro.2013.09.003","article-title":"Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings","volume":"24","author":"Gallini","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40263-013-0133-3","article-title":"A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer\u2019s disease in Europe: predictors of discontinuation and switch in the ICTUS study","volume":"28","author":"Gardette","year":"2014","journal-title":"CNS Drugs"},{"key":"B33","unstructured":"World alzheimer report 2022 \u2013 life after diagnosis: navigating treatment, care and support\n            GauthierS. W.\n            ServaesS.\n            MoraisJ.\n            Rosa-NetoP.\n          2022"},{"key":"B34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/02770903.2018.1439954","article-title":"Multifaceted interventions improve medication adherence and reduce acute hospitalization rates in medicaid patients prescribed asthma controllers","volume":"56","author":"Gelzer","year":"2019","journal-title":"J. Asthma"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/jgs.17172","article-title":"Trends in antipsychotic prescribing among long-term care residents receiving hospice care","volume":"69","author":"Gerlach","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"B36","unstructured":"Register of pharmacies of castile and Leon2023"},{"key":"B37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.amjopharm.2007.03.004","article-title":"Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population?","volume":"5","author":"Green","year":"2007","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1111\/jgs.17291","article-title":"Polypharmacy among older adults with dementia compared with those without dementia in the United States","volume":"69","author":"Growdon","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1266034","DOI":"10.3389\/fphar.2023.1266034","article-title":"Medication economic burden of antidepressant non-adherence in Spain","volume":"14","author":"Guti\u00e9rrez-Abej\u00f3n","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/WAD.0000000000000006","article-title":"Medication adherence in patients with dementia: an Austrian cohort study","volume":"28","author":"Haider","year":"2014","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1060028014563266","article-title":"Prescriber continuity and medication adherence for complex patients","volume":"49","author":"Hansen","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/j.1532-5415.2007.01377.x","article-title":"A population-based study of cholinesterase inhibitor use for dementia","volume":"55","author":"Herrmann","year":"2007","journal-title":"J. Am. Geriatr. Soc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ahj.2007.12.011","article-title":"Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease","volume":"155","author":"Ho","year":"2008","journal-title":"Am. Heart J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1468-1331.2010.03040.x","article-title":"EFNS guidelines for the diagnosis and management of Alzheimer\u2019s disease","volume":"17","author":"Hort","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/RMHP.S19801","article-title":"Adherence and health care costs","volume":"7","author":"Iuga","year":"2014","journal-title":"Risk Manag. Healthc. Policy"},{"key":"B48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1524-4733.2009.00543.x","article-title":"Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia","volume":"12","author":"Karve","year":"2009","journal-title":"Value Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00228-017-2388-y","article-title":"Measuring medication adherence in older community-dwelling patients with multimorbidity","volume":"74","author":"Kim","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/jgs.14226","article-title":"Treatment patterns with antidementia drugs in the United States: medicare cohort study","volume":"64","author":"Koller","year":"2016","journal-title":"J. Am. Geriatr. Soc."},{"key":"B52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/13696998.2018.1534739","article-title":"Compliance and persistence with Alzheimer\u2019s disease treatment: a retrospective analysis of multiregional hospital databases in Thailand","volume":"22","author":"Kongpakwattana","year":"2019","journal-title":"J. Med. Econ."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.4088\/JCP.14m09531","article-title":"Adherence to antidepressants is associated with lower mortality: a 4-year population-based cohort study","volume":"77","author":"Krivoy","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2165\/11538230-000000000-00000","article-title":"Discontinuation of cholinesterase inhibitor treatment and determinants thereof in The Netherlands: a retrospective cohort study","volume":"27","author":"Kr\u00f6ger","year":"2010","journal-title":"Drugs Aging"},{"key":"B55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/1533317517734639","article-title":"Can persistence with cholinesterase inhibitor treatment lower mortality and health-care costs among patients with alzheimer\u2019s disease? A population-based study in taiwan","volume":"33","author":"Ku","year":"2018","journal-title":"Am. J. Alzheimers Dis. Other Demen"},{"key":"B56","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"B57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/WAD.0b013e31819d6ec9","article-title":"Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia","volume":"24","author":"Lau","year":"2010","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B58","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1741-6612.2011.00564.x","article-title":"Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer\u2019s disease","volume":"31","author":"Le Couteur","year":"2012","journal-title":"Australas. J. Ageing"},{"key":"B59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/pharmacy10040087","article-title":"Adherence to and persistence with adalimumab therapy among Swedish patients with crohn\u2019s disease","volume":"10","author":"Liu","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"706762","DOI":"10.3389\/fphar.2021.706762","article-title":"Gender disparities in anti-dementia medication use among older adults: health equity considerations and management of alzheimer\u2019s disease and related dementias","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/ageing\/afp202","article-title":"Prediction of institutionalization in the elderly. A systematic review","volume":"39","author":"Luppa","year":"2010","journal-title":"Age Ageing"},{"key":"B63","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cger.2012.01.008","article-title":"Medication adherence to multidrug regimens","volume":"28","author":"Marcum","year":"2012","journal-title":"Clin. Geriatr. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jalz.2018.06.3063","article-title":"Racial and ethnic estimates of Alzheimer\u2019s disease and related dementias in the United States (2015-2060) in adults aged \u226565 years","volume":"15","author":"Matthews","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B65","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B66","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/070674371405901203","article-title":"Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors","volume":"59","author":"Maxwell","year":"2014","journal-title":"Can. J. Psychiatry"},{"key":"B132","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.14681331.2006.01409.x","article-title":"Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer\u2019s dementia in a randomized placebo-controlled double-blind study","volume":"13","author":"Mazza","year":"2006","journal-title":"Eur. J. neurology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.1468-1331.2006.01409.x","article-title":"Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer\u2019s dementia in a randomized placebo-controlled double-blind study","volume":"13","author":"M","year":"2006","journal-title":"Eur. J. neurology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1586\/ern.11.178","article-title":"Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer\u2019s disease","volume":"12","author":"Molinuevo","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"B69","doi-asserted-by":"publisher","first-page":"451","DOI":"10.18553\/jmcp.2008.14.5.451","article-title":"Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer\u2019s disease","volume":"14","author":"Mucha","year":"2008","journal-title":"J. Manag. Care Pharm."},{"key":"B70","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am. J. Med."},{"key":"B71","volume-title":"Dementia: a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care","year":"2007"},{"key":"B72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ageing\/afu143","article-title":"Systematic review of recent dementia practice guidelines","volume":"44","author":"Ngo","year":"2015","journal-title":"Age Ageing"},{"key":"B73","doi-asserted-by":"publisher","first-page":"CD000011","DOI":"10.1002\/14651858.CD000011.pub4","article-title":"Interventions for enhancing medication adherence","volume":"2014","author":"Nieuwlaat","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/1533317518787314","article-title":"Prevalence and incidence of statin use and 3-year adherence and discontinuation rates among older adults with dementia","volume":"33","author":"Ofori-Asenso","year":"2018","journal-title":"Am. J. Alzheimers Dis. Other Demen"},{"key":"B76","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000345279","article-title":"Persistence of cholinesterase inhibitor treatment in dementia: insights from a naturalistic study","volume":"3","author":"Olazar\u00e1n","year":"2013","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/alz.12753","article-title":"Alzheimer\u2019s disease medication use and adherence patterns by race and ethnicity","volume":"19","author":"Olchanski","year":"2023","journal-title":"Alzheimers Dement."},{"key":"B78","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s41999-023-00777-y","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 3","volume":"14","author":"O\u2019Mahony","year":"2023","journal-title":"Eur. Geriatr. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.2020.4683","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"B80","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"163","DOI":"10.30827\/ars.v59i3.7387","article-title":"M\u00e9todos para medir la adherencia terape\u00fatica","volume":"59","author":"Pag\u00e8s-Puigdemont","year":"2018","journal-title":"Ars Pharm."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e0169463","DOI":"10.1371\/journal.pone.0169463","article-title":"The association between polypharmacy and dementia: a nested case-control study based on a 12-year longitudinal cohort database in South Korea","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"key":"B83","article-title":"World alzheimer report 2018","volume-title":"The state of the art of dementia research: new frontiers","author":"Patterson","year":"2018"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.3390\/pharmaceutics14122696","article-title":"Non-adherence to antidepressant treatment and related factors in a region of Spain: a population-based registry study","volume":"14","author":"Pedrosa-Naud\u00edn","year":"2022","journal-title":"Pharmaceutics"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1206572","DOI":"10.3389\/fnagi.2023.1206572","article-title":"Current and future therapeutic strategies for Alzheimer\u2019s disease: an overview of drug development bottlenecks","volume":"15","author":"Peng","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1345\/aph.1L368","article-title":"Racial\/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study","volume":"43","author":"Poon","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"afad094","DOI":"10.1093\/ageing\/afad094","article-title":"Trends in the use of psychotropics in older people with dementia: interrupted time series of Finnish clinical guidelines of behavioural and psychological symptoms of dementia","volume":"52","author":"Rantsi","year":"2023","journal-title":"Age Ageing"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e2986","DOI":"10.1136\/bmj.e2986","article-title":"Cholinesterase inhibitors and memantine for symptomatic treatment of dementia","volume":"344","author":"Rodda","year":"2012","journal-title":"BMJ"},{"key":"B89","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00127-014-0911-3","article-title":"Institutionalization in incident dementia cases in comparison to age- and sex-matched controls: a 5-year follow-up from Germany","volume":"50","author":"Schulze","year":"2015","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","article-title":"Galantamine: a review of its use in Alzheimer\u2019s disease","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"B91","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00228-020-02995-w","article-title":"Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia","volume":"77","author":"Scuteri","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1186\/s12889-015-2493-8","article-title":"Monitoring patients on chronic treatment with antidepressants between 2003 and 2011: analysis of factors associated with compliance","volume":"15","author":"Serna","year":"2015","journal-title":"BMC Public Health"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1185\/030079907x233403","article-title":"A review of compliance to treatment in Alzheimer\u2019s disease: potential benefits of a transdermal patch","volume":"23","author":"Small","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"B94","unstructured":"Galantamine (Reminyl\u00ae): increased mortality in patients with mild cognitive impairment. Preliminary data from two clinical trials2005"},{"key":"B95","unstructured":"Comprehensive alzheimer\u2019s and other dementias plan (2019-2023)2019"},{"key":"B96","unstructured":"Demographics and population"},{"key":"B97","unstructured":"Type of health coverage"},{"key":"B98","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5414\/CP203670","article-title":"The role of the treating practice in persistence among dementia patients in Germany and the UK","volume":"58","author":"Steininger","year":"2020","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/ncprheum0652","article-title":"Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages","volume":"3","author":"Suissa","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000454948","article-title":"Comedication and treatment length in users of acetylcholinesterase inhibitors","volume":"7","author":"Sverdrup Efjestad","year":"2017","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"B101","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/YIC.0000000000000032","article-title":"Antidementia drug use among community-dwelling individuals with Alzheimer\u2019s disease in Finland: a nationwide register-based study","volume":"29","author":"Taipale","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B102","volume-title":"Demonstrating value with real world data: a practical guide","year":"2011"},{"key":"B103","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1503\/cmaj.071540","article-title":"Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis","volume":"179","author":"Valiyeva","year":"2008","journal-title":"CMAJ"},{"key":"B104","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13643-017-0572-x","article-title":"Comparative safety and efficacy of pharmacological and non-pharmacological interventions for the behavioral and psychological symptoms of dementia: protocol for a systematic review and network meta-analysis","volume":"6","author":"Watt","year":"2017","journal-title":"Syst. Rev."},{"key":"B106","unstructured":"Medication safety in polypharmacy: technical report2019"},{"key":"B107","unstructured":"ATC\/DDD index2020"},{"key":"B108","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40266-016-0372-3","article-title":"Pharmacotherapy for dementia: a practical approach to the use of cholinesterase inhibitors and memantine","volume":"33","author":"Wong","year":"2016","journal-title":"Drugs Aging"},{"key":"B109","unstructured":"International statistical classification of diseases and related health problems, ICD-10 Volume 22016"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e0130993","DOI":"10.1371\/journal.pone.0130993","article-title":"The effects of anti-dementia and nootropic treatments on the mortality of patients with dementia: a population-based cohort study in taiwan","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"B111","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S1474-4422(15)00092-7","article-title":"Dementia in western Europe: epidemiological evidence and implications for policy making","volume":"15","author":"Wu","year":"2016","journal-title":"Lancet Neurol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"e12014","DOI":"10.1002\/trc2.12014","article-title":"Prescription patterns of antidementives in a high income country: a pharmacoepidemiologic study","volume":"6","author":"Wurm","year":"2020","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B113","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/psyg.12568","article-title":"Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China","volume":"20","author":"Yu","year":"2020","journal-title":"Psychogeriatrics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1425442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T23:34:40Z","timestamp":1730763280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1425442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":112,"alternative-id":["10.3389\/fphar.2024.1425442"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1425442","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"article-number":"1425442"}}